Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

R Hehlmann

Showing results (271-280 of 310) with videos related to

Pageof 31
Sort By:
Leukemia|February 26, 2015
Interferon alpha 2 maintenance therapy may enable high rates of treatment discontinuation in chronic myeloid leukemiaA Burchert, S Saussele, E Eigendorff, et al.
Leukemia|July 3, 2002
Safety and efficacy of STI-571 (imatinib mesylate) in patients with bcr/abl-positive chronic myelogenous leukemia (CML) after autologous peripheral blood stem cell transplantation (PBSCT)T Fischer, C Reifenrath, G R Hess, et al.
Science (New York, N.Y.)|September 25, 2001
Roots of clinical resistance to STI-571 cancer therapyA Hochhaus, S Kreil, A Corbin, et al.
Leukemia|April 15, 2005
Gender aspects in chronic myeloid leukemia: long-term results from randomized studiesU Berger, O Maywald, M Pfirrmann, et al.
Blood|November 8, 2001
ABL-BCR expression does not correlate with deletions on the derivative chromosome 9 or survival in chronic myeloid leukemiaJ de la Fuente, K Merx, E J Steer, et al.
Leukemia|October 17, 2003
Marrow fibrosis, indicator of therapy failure in chronic myeloid leukemia - prospective long-term results from a randomized-controlled trialG Buesche, R Hehlmann, H Hecker, et al.
Leukemia|February 3, 2006
Cytogenetic response to prior treatment with interferon-alpha is predictive for survival after allogeneic hematopoietic stem cell transplantation in chronic myeloid leukemiaO Maywald, M Pfirrmann, U Berger, et al.
Leukemia|April 1, 1997
Randomized studies with interferon in chronic myelogenous leukemia (CML) and comparative molecular aspects. German CML Study GroupR Hehlmann, A Willer, H Heimpel, et al.
Bone Marrow Transplantation|June 19, 1998
Chemotherapy-induced mobilization of karyotypically normal PBSC for autografting in CMLT Fischer, A Neubauer, J Mohm, et al.
Leukemia|October 26, 2002
Molecular and chromosomal mechanisms of resistance to imatinib (STI571) therapyA Hochhaus, S Kreil, A S Corbin, et al.
Pageof 31

Showing results (271-280 of 310) with videos related to

Sort By:
Pageof 31
Leukemia|February 26, 2015
Interferon alpha 2 maintenance therapy may enable high rates of treatment discontinuation in chronic myeloid leukemiaA Burchert, S Saussele, E Eigendorff, et al.
Leukemia|July 3, 2002
Safety and efficacy of STI-571 (imatinib mesylate) in patients with bcr/abl-positive chronic myelogenous leukemia (CML) after autologous peripheral blood stem cell transplantation (PBSCT)T Fischer, C Reifenrath, G R Hess, et al.
Science (New York, N.Y.)|September 25, 2001
Roots of clinical resistance to STI-571 cancer therapyA Hochhaus, S Kreil, A Corbin, et al.
Leukemia|April 15, 2005
Gender aspects in chronic myeloid leukemia: long-term results from randomized studiesU Berger, O Maywald, M Pfirrmann, et al.
Blood|November 8, 2001
ABL-BCR expression does not correlate with deletions on the derivative chromosome 9 or survival in chronic myeloid leukemiaJ de la Fuente, K Merx, E J Steer, et al.
Leukemia|October 17, 2003
Marrow fibrosis, indicator of therapy failure in chronic myeloid leukemia - prospective long-term results from a randomized-controlled trialG Buesche, R Hehlmann, H Hecker, et al.
Leukemia|February 3, 2006
Cytogenetic response to prior treatment with interferon-alpha is predictive for survival after allogeneic hematopoietic stem cell transplantation in chronic myeloid leukemiaO Maywald, M Pfirrmann, U Berger, et al.
Leukemia|April 1, 1997
Randomized studies with interferon in chronic myelogenous leukemia (CML) and comparative molecular aspects. German CML Study GroupR Hehlmann, A Willer, H Heimpel, et al.
Bone Marrow Transplantation|June 19, 1998
Chemotherapy-induced mobilization of karyotypically normal PBSC for autografting in CMLT Fischer, A Neubauer, J Mohm, et al.
Leukemia|October 26, 2002
Molecular and chromosomal mechanisms of resistance to imatinib (STI571) therapyA Hochhaus, S Kreil, A S Corbin, et al.
Pageof 31